Calpain 10 gene single-nucleotide 44 polymorphism may have been an influence on clinical and metabolic features in patients with polycystic ovary syndrome

PubMed: 19337008Aim: This study was designed in order to examine the relationship between Calpain 10 [single-nucleotide polymorphism (SNP) 19,43,44,63] gene polymorphisms and clinical and hormonal characteristics in women with polycystic ovary syndrome (PCOS). Materials and methods: One hundred and seven patients with PCOS and 114 healthy subjects were included in this study. Serum levels of sex steroids were measured for each individual. Insulin resistance (IR) was evaluated by the homeostasis model assessment (HOMA) and quantitative insulin-sensitivity check index (QUICKI) methods. Insulin and glucose responses to the oral glucose tolerance test (OGTT) were analyzed by calculating the areas under the curve for insulin (AUCI) and glucose by the trapezoidal methods. We used PCR and restriction fragment length polymorphism technique to examine Calpain 10 SNP 19,43,44, and 63 polymorphisms. Results: Allele distribution of Calpain 10 SNP 44 gene polymorphism was observed as significantly different between the groups. Calpain 10 SNP 44 TC genotype was found to be increased in PCOS subjects (69.15%) compared to the control subjects (50%). However, when compared to control subjects, patients with PCOS had similar Calpain 10 SNP 19, Calpain 10 SNP 43, and SNP 63 gene polymorphisms. When compared with normal Calpain 10 gene SNP 44 allele in PCOS subjects, subjects with PCOS having Calpain 10 gene SNP 44 allele polymorphism had higher free testosterone, androstenedione, DHEA-S, and fasting insulin levels. Also, PCOS women with Calpain 10 gene SNP 44 allele polymorphism had high Ferriman-Gallwey (F-G) score, acne, prevalence of menstrual disturbances, waist-hip ratio, HOMA-IR, AUCI levels and low QUICKI levels. Conclusion: The findings show that Calpain 10 gene SNP 44 allele polymorphism may have a role in PCOS pathogenesis. However, larger-scale studies are needed in this field. © 2009, Editrice Kurtis

Evaluation of the dose distribution behind the prostheses in prostate cancer patients with hip prostheses using film dosimetry and specially designed phantom [Kalça protezli prostat kanseri hastalari{dotless} için protez arkasi{dotless}ndaki doz dagi{dotless}li{dotless}mi{dotless}ni{dotless}n film dozimetre ve özel olarak tasarlanmi{dotless}ş fantom kullani{dotless}larak degerlendirilmesi]

OBJECTIVES: We aimed to investigate the effect of hip prostheses on dose distribution in radiotherapy patients. METHODS: Solid Water phantom-containing prostheses (cobalt-chromium-molybdenum and cobalt-chromium-molybdenum-titanium) were placed between the phantoms used for the measurements. Films at 10, 20 and 30 cm depths were irradiated for 6 and 18 MV with 50 cGy dose in the presence or not of prosthesis. Dose profiles were evaluated statistically. RESULTS: For 6 and 18 MV photon energies, significant differences was found along the thick and vertical axes of both prostheses at 10 and 20 cm depths and along the middle, thick and vertical axis at 30 cm depth (p<0.05). CONCLUSION: Hip prostheses affect radiotherapy dose distribution, and this should be considered when planning a treatment. © 2012 Association of Oncology